Research, Resources, Expertise & Funding

Sanger Research groups

Adams Group
Experimental Cancer Genetics
David Adams

The Adams Group aims to understand the biological role of genes influencing cancer development.

Garnett Group
Translational Cancer Genomics
Mathew Garnett

We investigate how abnormalities in the DNA of cells contribute to cancer and impact on patient responses to therapy. This provides fundamental insights into disease mechanisms with implications for the development of improved therapies.

McDermott Group
Cancer Functional Genomics
Ultan McDermott

Our work is in the understanding of how cancer genomes affect drug sensitivity and resistance. Ultimately our goal is to create knowledge of what drives drug response and resistance in cancer that will be of benefit to patients.

Yusa Group
Stem Cell Genetics
Kosuke Yusa

The Yusa laboratory focuses on the development of genome engineering technologies that allow us to perform unbiased genome-wide genetic screens in mammalian cells. We have recently adopted the CRISPR-Cas9 technology as a screening tool and generated genome-scale lentiviral CRISPR libraries.

Parts Group
Genetic Screens of Cellular Traits
Leopold Parts

We develop probabilistic models and software tools to accurately analyse the readouts of CRISPR/Cas9 based genetic screens.

DepMap Collaborations

The Cancer Dependency Map at Sanger is part of the larger Cancer Dependency Map effort.

The DepMap is a strategic collaboration with the Broad Institute of MIT and Harvard. The work of the Broad Institute towards the cancer dependency map can be found at the Broad DepMap page.

Working Groups

DepMap Organizing Committee

The organizing committee includes leadership from contributing collaborators to coordinate efforts and provide strategic scientific direction.

Co-chairs: Jesse Boehm & Mathew Garnett

Models Working Group

This working group aims to define and execute a strategy to generate a collection of highly-annotated cancer models which recapitulate the genetic and histological diversity of human cancer.

Co-chairs: Hayley Francies & Moony Tseng

Analysis Working Group

The goal of the Analysis Working Group is to develop statistical methods and computational tools for analysing the DepMap data to identify and predict cancer vulnerabilities.

Co-chairs: Aviad Tsherniak & Francesco Iorio

CRISPR Technology Working Group

The CRISPR Technology Working Group aims to create highly-efficient genome-engineering libraries compatible with screening in cell lines and complex models such as organoids or short-term cultures.

Co-chairs: Fiona Behan & John Doench


The Cancer Dependency Map
The DepMap at Sanger is part of the larger Cancer Dependency Map effort, in collaboration with the Broad Institute.

COSMIC, the Catalogue Of Somatic Mutations In Cancer, is the world's largest and most comprehensive resource for exploring the impact of somatic mutations in human cancer.

WTSI Genome Editing
WTSI Genome Editing (WGE) is a website that provides tools to aid with genome editing of human and mouse genomes

Open Targets Platform
Comprehensive and robust data integration for access to and visualisation of potential drug targets associated with disease.

Human Cancer Model Initiative
An international consortium generating novel human tumor-derived culture models, which are annotated with genomic and clinical data.

CTD²: Cancer Target Discovery And Development
Bridges the gap between the enormous volumes of data generated by genomic characterization studies and the ability to use these data for the development of human cancer therapeutics.

Provides visualization, analysis and download of large-scale cancer genomics data sets.